Antihypertensive Class Labeling Public Health Impact Assessment Being Considered By FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Class labeling for antihypertensives on blood pressure reduction and cardiovascular outcomes to be discussed during an April 26 meeting.
You may also be interested in...
FDA Antihypertensive Draft Class Labeling To Be Reviewed By Cardio-Renal Committee
FDA’s proposal for relabeling of antihypertensive agents is based on prior recommendations by the committee that information on cardiovascular outcomes related to blood pressure lowering be included as class labeling.
Antihypertensive Indications Should Include Benefit On Cardiac Outcomes, Cmte. Says
Most conclusive benefit seen from lowering blood pressure is reduction of stroke, Cardiovascular & Renal Drugs Advisory Committee says. Products that have cardiac outcomes studies could include data in labeling, committee adds.
NME Slowdown Shows Market Pressure On Me-Toos, Not FDA Caution – Lutter
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter